Hyperprolactinemia in Men: Causes, Symptoms, and Treatment

Hyperprolactinemia, a sustained rise in the hormone prolactin, tends to go unnoticed in men far longer than in women, often reaching a diagnosis only after tumors have grown large or bone density has quietly dropped. Men lack the early warning sign that women get from disrupted menstrual cycles, so the condition frequently surfaces through sexual symptoms like low libido and erectile trouble, or through headaches and vision changes caused by a pituitary mass pressing on nearby structures. The causes range from common medications to rare tumors, and treatment usually works well once the diagnosis is made, though it carries its own set of side effects worth understanding.

Why Men Tend to Get Diagnosed Late

Women with rising prolactin levels typically notice irregular or absent periods early on, prompting medical workups that catch the problem when tumors are still small. Men have no equivalent monthly signal. The most common presenting symptoms in men with prolactin-secreting pituitary tumors are headaches and visual field defects caused by the tumor pushing against surrounding brain structures, not the hormonal symptoms themselves. One study of macroprolactinomas found that over 93% of men presented with these mass-effect symptoms, while 96% of women presented with hormonal complaints like menstrual irregularity or infertility.¹

By the time men seek care, their tumors are typically larger. In the same study, the average maximum tumor dimension in men was about 3.9 cm compared to 2.5 cm in women, and baseline prolactin levels were roughly two and a half times higher. A separate surgical series confirmed that men had significantly larger tumors with more frequent extension into the cavernous sinus and the area above the pituitary, both signs of a more advanced growth.² Giant prolactinomas, defined as tumors larger than 4 cm with prolactin levels above 1,000 ng/mL and invasive growth, occur mostly in men.³

What Causes Prolactin Levels to Rise

Prolactin secretion from the pituitary gland is held in check by dopamine, which acts as a constant brake. Anything that interferes with dopamine’s suppressive signal can allow prolactin to climb. The causes fall into a few broad categories.

Medications are the most common culprit, especially antipsychotics. Nearly all antipsychotics raise prolactin by blocking dopamine D2 receptors on the prolactin-producing cells of the anterior pituitary, removing the very signal that keeps secretion in check.⁴ Older “typical” antipsychotics and risperidone are among the strongest offenders, though most drugs in the class can do it.⁵ Other medications that can raise prolactin include certain antidepressants, anti-nausea drugs like metoclopramide, and some blood pressure medications. If medication is the cause, prolactin levels usually normalize after the drug is stopped or switched, though that decision has to be weighed against the psychiatric or medical condition the drug is treating.

Prolactinomas, benign tumors of the pituitary gland that secrete prolactin on their own, are the most common pituitary tumor type. They range from tiny microadenomas (under 1 cm) to massive growths. As noted, men tend to harbor larger prolactinomas by the time they are found.

Other pituitary and hypothalamic conditions can raise prolactin indirectly. A large non-functioning pituitary adenoma can compress the pituitary stalk, blocking dopamine’s path from the hypothalamus to the pituitary. This “stalk effect” produces a mild to moderate prolactin elevation, typically under about 150 ng/mL, which can mimic a small prolactinoma. Distinguishing stalk-effect hyperprolactinemia from a true prolactinoma matters because the treatments differ. A pilot study found that a cabergoline disconnection test, measuring how prolactin responds to a dopamine agonist challenge, could perfectly separate true prolactinomas from non-functioning adenomas when the post-test prolactin level was used as the criterion.⁶

Hypothyroidism, particularly underactive thyroid function that hasn’t been caught, can also push prolactin up. In a study of patients with subclinical hypothyroidism, about one in five had elevated prolactin, with the link more common in women than men.⁷ Correcting the thyroid problem usually fixes the prolactin issue too.

How Excess Prolactin Disrupts Hormones

The central problem prolactin causes in men is suppression of the reproductive hormone axis. Elevated prolactin reduces the activity of kisspeptin-producing neurons in the hypothalamus, which are key drivers of the signal that triggers the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).⁸ When LH and FSH drop, the testes receive less stimulation. The result is falling testosterone, reduced sperm production, and the constellation of symptoms that follow from both.

This hormonal cascade explains why the symptoms of hyperprolactinemia in men overlap so heavily with low testosterone: fatigue, loss of muscle mass, decreased body hair, reduced libido, and erectile difficulty. In some cases, men develop mild breast tissue growth or, rarely, galactorrhea (discharge from the nipple), which is far less common in men than in women with the condition.

Sexual Function and the Prolactin Connection

Low sex drive is one of the most consistent complaints in men with elevated prolactin. Meta-analytic evidence confirms a clear, stepwise negative relationship between prolactin levels and sexual desire in men, and bringing prolactin back to normal reliably restores libido.⁹ Decreased libido was also the symptom most strongly associated with male prolactinoma patients in a surgical series, appearing significantly more often in men than in women with the same tumors.²

Erectile dysfunction is a bit more complicated. Historically it was assumed that prolactin-related erection problems were simply a downstream effect of low testosterone. But recent research shows that prolactin can impair erections through its own separate pathway. A 2025 study found that elevated prolactin suppressed a signaling pathway involved in blood-vessel relaxation within erectile tissue, and this effect persisted even when testosterone levels were kept normal.¹⁰ That finding helps explain a clinical puzzle: some men with prolactinomas have erection trouble despite having acceptable testosterone levels.

However, normalizing prolactin only partially resolves erectile dysfunction in most men. The same meta-analytic data that showed a clear libido recovery found that treating hyperprolactinemia had a limited effect on erections themselves.⁹ Men with erectile dysfunction and low testosterone should have their prolactin checked, since a pituitary adenoma may be the treatable root cause.¹¹ But for erection problems specifically, additional treatments like phosphodiesterase inhibitors may still be needed even after prolactin levels come down.

Diagnostic Pitfalls

A single elevated prolactin reading doesn’t automatically mean something is wrong. Prolactin can spike temporarily from stress, exercise, a recent meal, or even the anxiety of a blood draw. Most clinicians confirm the finding with a repeat test. Beyond that, there are two lab artifacts that trip up doctors regularly.

The first is macroprolactinemia. In anywhere from 10% to 46% of patients found to have elevated prolactin, the high reading comes not from active prolactin but from large, biologically inactive complexes of prolactin bound to antibodies. These complexes register on the lab assay as elevated prolactin, but they don’t cause symptoms because the body can’t use them. Patients with macroprolactinemia are at risk of unnecessary imaging and treatment if the lab doesn’t specifically screen for this.¹² A simple additional lab step, typically involving precipitation with polyethylene glycol, can separate the inactive complexes from the real thing.

The second is the hook effect, which goes in the opposite direction. When prolactin levels are extremely high, as they can be with giant prolactinomas, the antibodies in the lab assay get saturated and the test paradoxically reads as only mildly elevated or even normal. This can lead a doctor to underestimate the severity of the situation, potentially mistaking a massive prolactinoma for a non-functioning tumor with stalk effect. Diluting the blood sample and re-running the test reveals the true, much higher prolactin level.¹³

Dopamine Agonist Therapy

Dopamine agonists are the first-line treatment for most cases of hyperprolactinemia caused by prolactinomas. These drugs mimic dopamine’s natural role in suppressing prolactin secretion and can shrink tumors, sometimes dramatically, in addition to normalizing hormone levels. The two main options are cabergoline and bromocriptine.

Cabergoline has largely become the preferred choice. It is taken just once or twice a week rather than daily, it causes fewer gastrointestinal side effects like nausea and dizziness, and pooled data across randomized trials show it is more effective at normalizing prolactin and resolving symptoms.¹⁴ Bromocriptine remains available and is sometimes preferred in specific situations, such as during pregnancy planning in women, though in men cabergoline is the standard starting drug in most endocrine practices.

Men with prolactinomas respond well to dopamine agonists despite often having larger tumors and higher prolactin levels than women. One study specifically confirmed that males with macroprolactinomas were equally responsive to cabergoline as females, even though their tumors were bigger at diagnosis.¹ Treatment typically starts at a low dose, with gradual increases guided by prolactin levels checked every few weeks to months.

Cardiac Valve Safety on Long-Term Treatment

The heart valve question is one that men on cabergoline inevitably encounter, either from their endocrinologist or from reading the drug’s prescribing information. Cabergoline belongs to the ergot-derived dopamine agonist family, and its chemical activity at serotonin receptors in heart valve tissue raised concern after studies in Parkinson’s disease found increased rates of valve regurgitation.¹⁵ The doses used for Parkinson’s, however, are far higher than the doses used for prolactinomas, sometimes ten to twenty times higher.

At the lower doses typical in prolactinoma treatment, the risk appears much smaller. One long-term study of cabergoline-treated prolactinoma patients found only mild valvular regurgitation in a few cases, no moderate or severe regurgitation, and no structural valve abnormalities like thickening or calcification.¹⁶ That said, case reports of isolated valve damage do exist, and the mechanism linking cabergoline’s serotonin activity to valve fibrosis is real.¹⁷ Most endocrine societies recommend periodic echocardiograms for patients on long-term cabergoline, with the frequency depending on dose and duration.

Impulse Control Disorders on Dopamine Agonists

A side effect that gets less attention than cardiac concerns but may be more immediately disruptive is the emergence of impulse control disorders during dopamine agonist therapy. These include compulsive gambling, compulsive shopping, hypersexuality, binge eating, and a behavior called punding, which involves repetitive, purposeless tasks.¹⁸ The irony is not lost on patients or clinicians: a drug prescribed partly because low libido prompted the diagnosis can, in some cases, swing drive in the other direction or trigger unrelated compulsive behaviors.

Men appear to be at higher risk. In a multicenter cross-sectional study, any impulse control disorder and hypersexuality specifically were both significantly more common in male patients on dopamine agonists compared to female patients.¹⁹ Other identified risk factors include younger age, smoking, alcohol use, and a history of depression.¹⁸ A case-control study focusing specifically on cabergoline found that treated patients had more than four times the odds of compulsive shopping compared to controls, along with higher overall impulsivity scores.²⁰

These behaviors often go unreported unless patients and their partners are specifically warned to watch for them. Anyone starting a dopamine agonist should be told in advance what to look for, and clinicians should ask about these symptoms at follow-up visits.

When Medication Doesn’t Work

A minority of prolactinomas resist dopamine agonists, meaning prolactin levels don’t normalize or the tumor doesn’t shrink adequately even at maximum tolerable doses. For these patients, transsphenoidal surgery, performed through the nose and sinuses to reach the pituitary, becomes the next step. The goal can be complete tumor removal for smaller growths or debulking for larger ones, which may improve the tumor’s response to medication afterward.²¹

Surgical outcomes depend heavily on tumor size. In one retrospective study of 94 dopamine agonist-resistant patients, about 73% of those with microprolactinomas achieved early remission after surgery, compared to about 41% of those with macroprolactinomas. Total resection rates followed the same pattern, with roughly 96% complete removal for small tumors but 75% for larger ones. Recurrence of elevated prolactin happened in about 32% of patients over a follow-up period averaging around three years.²²

For patients with aggressive prolactinomas that persist despite both medication and surgery, radiotherapy is sometimes considered, though it is slow to take effect. Normal prolactin levels are eventually achieved in only about a third of irradiated patients, and it may take years.²¹

Fertility Recovery

Hyperprolactinemia is a treatable cause of male infertility, and this is one of the more encouraging aspects of the condition. When prolactin levels come down with dopamine agonist therapy, the hypothalamic-pituitary-gonadal axis typically restarts. Treatment with dopamine agonists has been shown to significantly improve both semen quality and hormone levels in infertile men with confirmed hyperprolactinemia.²³

Even in difficult cases, creative treatment combinations can work. One case report described a man with a medication-resistant macroprolactinoma who achieved fertility using high-dose bromocriptine alongside gonadotropin injections and an aromatase inhibitor. The combination brought his prolactin near normal, shrank the tumor, restored testosterone, returned his sperm count, and ultimately resulted in a pregnancy.²⁴ Recovery isn’t always that dramatic, but the general trajectory, that treating hyperprolactinemia can restore reproductive function in men, is well supported.

Bone Health

Bone loss is one of the quieter consequences of hyperprolactinemia in men, but the data on it are striking. In a long-term follow-up of prolactinoma patients, impaired bone mineral density was recorded in 37% of men compared to 7% of women at last follow-up. Male sex was the strongest independent risk factor for long-term bone impairment, with over sixteen times the odds compared to female sex. Persistent hyperprolactinemia was also an independent risk factor, while persistent hypogonadism alone did not reach statistical significance.²⁵

What makes this finding more troubling is that bone density did not significantly improve even after prolactin and testosterone were brought back to normal levels. The title of that study says it plainly: bone impairment persisted despite long-term hormonal control. This suggests that the damage to bone may happen during the undiagnosed period and doesn’t fully reverse, which is another argument for catching the condition earlier in men. The same finding has been reflected in case reports of young men with prolactinomas who showed bone density well below what would be expected for their age.²⁶

Metabolic Effects Beyond Hormones

Hyperprolactinemia doesn’t only disrupt reproductive hormones. There is growing evidence that elevated prolactin is linked to insulin resistance, which is the body’s reduced ability to respond to insulin and a precursor to type 2 diabetes and metabolic syndrome. Multiple studies have identified a relationship between high prolactin and increased insulin resistance, with proposed mechanisms including prolactin’s role in regulating insulin sensitivity in fat tissue and its synergistic effect with glucose on insulin gene activity.²⁷

The connection appears even within normal prolactin ranges. A study in non-diabetic men found that higher prolactin levels within the physiological range were associated with greater insulin resistance, with the relationship strongest below a threshold of about 12 ng/mL.²⁸ Whether treating hyperprolactinemia directly improves metabolic outcomes is still being studied, but the association adds one more reason not to dismiss mildly elevated prolactin levels as clinically unimportant in men, particularly those who already have metabolic risk factors.

1
PubMed Central. Gender differences in macroprolactinomas: a single centre experience
2
PubMed Central. Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention
3
PubMed Central. Rapid Improvement of Visual Field Defect with Medical Treatment in Giant Prolactinoma with Optic Nerve Compression
4
Progress in Neuro-Psychopharmacology & Biological Psychiatry. Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management
5
Prescriber Update. Hyperprolactinaemia With Antipsychotics
6
PubMed Central. A new and useful tool for differentiating prolactinomas from non-functioning pituitary adenomas: a pilot study of the cabergoline disconnection test
7
PubMed Central. Hyperprolactinemia in association with subclinical hypothyroidism
8
The Journal of Clinical Investigation. Hyperprolactinemia and infertility: new insights
9
PubMed. Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire
10
PubMed. Prolactin impairs erectile function via eNOS suppression independently of testosterone
11
PubMed Central. Hyperprolactinemia and erectile dysfunction
12
PubMed Central. Macroprolactinemia: a mini-review and update on clinical practice
13
Endocrine Practice. Hyperprolactinemia in Men: Causes, Symptoms, and Treatment – Section: RESULTS
14
Medwave. Cabergoline or bromocriptine for prolactinoma?
15
PubMed. Dopamine agonists and the risk of cardiac-valve regurgitation
16
PubMed Central. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
17
PubMed Central. The Silent Valve Culprit: A Case Report and Literature Review of Isolated Cabergoline-Induced Mitral Regurgitation
18
PubMed. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy
19
The Journal of Clinical Endocrinology & Metabolism. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study
20
PubMed Central. Increased impulsivity and higher odds of compulsive shopping among cabergoline-treated patients with prolactinoma: a case-control study
21
PubMed. Management of Dopamine Agonist-Resistant Prolactinoma
22
PubMed. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study
23
PubMed Central. Hyperprolactinaemia in male infertility: Clinical case scenarios
24
PubMed. Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor
25
Scientific Reports. Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
26
PubMed Central. Prolactinoma: A Massive Effect on Bone Mineral Density in a Young Patient
27
PubMed. Hyperprolactinemia and insulin resistance
28
PubMed Central. Association between serum prolactin levels and insulin resistance in non-diabetic men